These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22862294)

  • 1. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
    Bolli MH; Boss C; Binkert C; Buchmann S; Bur D; Hess P; Iglarz M; Meyer S; Rein J; Rey M; Treiber A; Clozel M; Fischli W; Weller T
    J Med Chem; 2012 Sep; 55(17):7849-61. PubMed ID: 22862294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.
    Bolli MH; Marfurt J; Grisostomi C; Boss C; Binkert C; Hess P; Treiber A; Thorin E; Morrison K; Buchmann S; Bur D; Ramuz H; Clozel M; Fischli W; Weller T
    J Med Chem; 2004 May; 47(11):2776-95. PubMed ID: 15139756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M; Bossu A; Wanner D; Bortolamiol C; Rey M; Hess P; Clozel M
    Life Sci; 2014 Nov; 118(2):333-9. PubMed ID: 24582812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis.
    Raja SG
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1066-73. PubMed ID: 20730702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
    Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
    J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.
    Sen S; Chen S; Feng B; Iglarz M; Chakrabarti S
    Life Sci; 2012 Oct; 91(13-14):658-68. PubMed ID: 22525377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
    Bolli MH; Boss C; Clozel M; Fischli W; Hess P; Weller T
    Bioorg Med Chem Lett; 2003 Mar; 13(5):955-9. PubMed ID: 12617929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats.
    Yuyama H; Sonoda R; Shibasaki K; Fujimori A; Sudoh K; Sasamata M; Miyata K
    Vascul Pharmacol; 2004 Feb; 41(1):27-34. PubMed ID: 15135329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
    Amberg W; Hergenröder S; Hillen H; Jansen R; Kettschau G; Kling A; Klinge D; Raschack M; Riechers H; Unger L
    J Med Chem; 1999 Aug; 42(16):3026-32. PubMed ID: 10447946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
    Yuyama H; Sanagi M; Koakutsu A; Mori M; Fujimori A; Harada H; Sudoh K; Miyata K
    Eur J Pharmacol; 2003 Sep; 478(1):61-71. PubMed ID: 14555186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3355-68. PubMed ID: 11585441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
    Sidharta PN; Krähenbühl S; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Discovery of Macitentan - A Standard Medicinal Chemistry Program?
    Bolli MH
    Chimia (Aarau); 2017 Aug; 71(7):420-429. PubMed ID: 28779766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
    Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
    J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.